Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2024 | $8.00 | Buy | H.C. Wainwright |
| 8/3/2021 | $20.00 | Outperform | Oppenheimer |
| 8/2/2021 | $20.00 | Outperform | Oppenheimer |
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri's ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and nine months ended September 30, 2024. "We continued to make progres
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast cancer HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer. "Dosi
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announces that management will be participating in the following investor and industry conferences during the month of September: H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, at the Lotte New York Palace Hotel. Management will be holding one-on-one meetings with investors and will deliver a company presentation. The recorded presentation will be available on demand beginning Monday, September 9th at 7:00am Eastern time on the Investors section of Processa's website and here.European Society for Medical Oncology (ESMO) Congress 2024, September 13-17, 2024, in Bar
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma (NASDAQ:PCSA) with a Buy and maintains $8 price target.
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri's ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and nine months ended September 30, 2024. "We continued to make progres
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provides updates on its product pipeline, upcoming milestones and business activities, and reports financial results for the three and six mont
HANOVER, MD, March 23, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023. Conference Call Information To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call. Date: March 30, 2023Time: 4:30 p.m. ETToll Free: 888-506-0062Internatio
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Russell L. Skibsted as Chief Financial Officer (CFO), effective immediately. Mr. Skibsted succeeds James Stanker, who is retiring and staying on in an advisory role to assist in the transition. "We are delighted to welcome Russell to Processa's executive team. His proven record in finance and capital markets combined with a deep understanding of the complexities inherent in the life sciences make him a
FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design HANOVER, MD, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it plans to expand the development of Next Generation Capecitabine ("NGC-Cap") into the treatment of advanced or metastatic breast cancer beginning with its ne
HANOVER, MD, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran George Ng has been appointed to serve as the Company's Chief Executive Officer and as a Board Director as of August 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy (NGC) drugs as President of Research and Development and as a board member. "We are thrilled to have George assume the leadership of ou
8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
10-Q - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
H.C. Wainwright initiated coverage of AirGate PCS with a rating of Buy and set a new price target of $8.00
Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00
Oppenheimer initiated coverage of Processa Pharmaceuticals with a rating of Outperform and set a new price target of $20.00
SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
SC 13G - Processa Pharmaceuticals, Inc. (0001533743) (Subject)
SC 13G/A - Processa Pharmaceuticals, Inc. (0001533743) (Subject)